GlobeNewswire by notified

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

Share

Company Announcement

COPENHAGEN, Denmark; November 14, 2022Genmab A/S (Nasdaq:GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of the transactions made in Genmab A/S (Nasdaq: GMAB) made by managerial employees and their closely associated persons.

The company’s managerial employees and their closely associated persons have given Genmab A/S power of attorney on their behalf to publish trading in Genmab shares by the company’s managerial employees and their closely associated persons.

About Genmab
Genmab is an international biotechnology company with a core purpose to improve the lives of people with cancer. For more than 20 years, Genmab’s vision to transform cancer treatment has driven its passionate, innovative and collaborative teams to invent next-generation antibody technology platforms and leverage translational research and data sciences, fueling multiple differentiated cancer treatments that make an impact on people’s lives. To develop and deliver novel therapies to patients, Genmab has formed 20+ strategic partnerships with biotechnology and pharmaceutical companies. Genmab’s proprietary pipeline includes bispecific T-cell engagers, next-generation immune checkpoint modulators, effector function enhanced antibodies and antibody-drug conjugates.

Genmab is headquartered in Copenhagen, Denmark with locations in Utrecht, the Netherlands, Princeton, New Jersey, U.S. and Tokyo, Japan. For more information, please visit Genmab.com and follow us on Twitter.com/Genmab.

Contact:
Marisol Peron, Senior Vice President, Communications and Corporate Affairs
T: +1 609 524 0065; E: mmp@genmab.com

Andrew Carlsen, Vice President, Head of Investor Relations
T: +45 3377 9558; E: acn@genmab.com

This Company Announcement contains forward looking statements. The words “believe”, “expect”, “anticipate”, “intend” and “plan” and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with pre-clinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products or technologies obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab’s most recent financial reports, which are available on www.genmab.comand the risk factors included in Genmab’s most recent Annual Report on Form 20-Fand other filingswith the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov.Genmab does not undertake any obligation to update or revise forward looking statements in this Company Announcement nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law.

Genmab A/S and/or its subsidiaries own the following trademarks: Genmab®; the Y-shaped Genmab logo®; Genmab in combination with the Y-shaped Genmab logo®; HuMax®; DuoBody®; DuoBody in combination with the DuoBody logo®; HexaBody®;HexaBody in combination withthe HexaBody logo®; DuoHexaBody® and HexElect®.



CVR no. 2102 3884
LEI Code 529900MTJPDPE4MHJ122

Genmab A/S
Kalvebod Brygge 43
1560 Copenhagen V
Denmark

Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

The Board of Directors of Talenom Plc has decided on a directed share issue as part of acquisitions1.2.2023 15:40:00 CET | Press release

Talenom Plc, Stock Exchange Release 1 February 2023 at 16:40 EET The Board of Directors of Talenom Plc has decided on a directed share issue as part of acquisitions Talenom Plc announced two acquisitions on 1 February 2023. Part of the purchase prices will be paid in cash and part with new shares of Talenom Plc subscribed in a directed share issue. The transaction prices are not disclosed. As part of the transactions, Talenom has decided to issue 50,825 new shares in a directed share issue for the sellers of the acquisition targets, i.e., BKF Asesores, S.L. and R2 Redovisning Ab. The subscription date for the shares is 1 February 2023. The number of new shares to be issued corresponds with some 0.11 percent of all Talenom Plc's shares prior to the share issue. After the registration of the new shares the total number of shares in Talenom Plc is 44,986,213 shares. The new shares will carry shareholder rights as of their registration day, estimated on 3 February 2023. The shares issued i

Talenom expands its operations in Spain by acquiring an accounting firm in Madrid1.2.2023 15:35:00 CET | Press release

Talenom Plc, press release 1 February 2023 at 16:35 EET Talenom expands its operations in Spain by acquiring an accounting firm in Madrid Talenom Plc has agreed to acquire the entire share capital of BKF Asesores, S.L., an accounting firm operating in Madrid, Spain. The acquired business will be transferred to Talenom on 1 February 2023. BKF Asesores, S.L. provides accounting, payroll and advisory services mainly to SMEs. The net sales transferred to Talenom from the acquired business is some EUR 0.7 million annually. The company employs a total of nine persons who will continue to work for Talenom. In the short term, the acquisition will not have any significant impact on Talenom’s financial position or future outlook. Talenom combines software development with expertise in the accounting industry in a unique way. The aim of the company is to grow both organically and through acquisitions in Finland and in Europe. Further information: Otto-Pekka Huhtala CEO, Talenom Plc +358 40 703 85

Talenom acquires the Swedish accounting firm R2 Redovisning Ab1.2.2023 15:30:00 CET | Press release

Talenom Plc, press release 1 February 2023 16:30 EET Talenom acquires the Swedish accounting firm R2 Redovisning Ab Talenom Plc has agreed to acquire the entire share capital of R2 Redovisning Ab. The acquired business will be transferred to Talenom on 1 February 2023. R2 Redovisning Ab operates in Gothenburgh and Kungsbacka. The company provides accounting, payroll and advisory services mainly to SMEs. The yearly net sales transferred to Talenom from the acquired business is approximately EUR 0.7 million. The company employs a total of seven persons who will continue to work for Talenom. In the short term, the acquisition will not have any significant impact on Talenom’s financial position or future outlook. Talenom combines software development with expertise in the accounting industry in a unique way. The aim of the company is to grow both organically and through acquisitions in Finland and in Europe. Further information: Otto-Pekka Huhtala CEO, Talenom Plc +358 40 703 8554 otto-pek

Ordinær generalforsamling Ringkjøbing Landbobank A/S1.2.2023 15:28:56 CET | pressemeddelelse

Nasdaq Copenhagen London Stock Exchange Euronext Dublin Øvrige interessenter Dato 01.02.2023 Ordinær generalforsamling i Ringkjøbing Landbobank A/S Der afholdes ordinær generalforsamling onsdag, den 1. marts 2023, kl. 17.00 i ROFI-Centret, Kirkevej 26, Rindum, 6950 Ringkøbing. Dagsorden i henhold til vedtægterne 1. Valg af dirigent Bestyrelsen foreslår advokat Allan Østergaard Sørensen som dirigent. 2.Bestyrelsens beretning om bankens virksomhed i det forløbne år Bestyrelsen foreslår, at bestyrelsens beretning tages til efterretning. 3.Fremlæggelse af årsrapporten til godkendelse Bestyrelsen foreslår, at årsrapporten godkendes. Der henvises endvidere til den offentliggjorte årsrapport for 2022. 4.Beslutning om anvendelse af overskud eller dækning af tab i henhold til den godkendte årsrapport Bestyrelsen foreslår, at resultatdisponeringen godkendes. Der henvises endvidere til den offentliggjorte årsrapport for 2022. 5.Vejledende afstemning om vederlagsrapport Bestyrelsen foreslår, at ve

Annual general meeting of Ringkjøbing Landbobank A/S1.2.2023 15:28:56 CET | Press release

Nasdaq Copenhagen London Stock Exchange Euronext Dublin Other stakeholders Date 01.02.2023 Annual general meeting of Ringkjøbing Landbobank A/S The bank will hold its annual general meeting at 5:00 p.m. on Wednesday, 1 March 2023 at the ROFI Centre, Kirkevej 26, Rindum, 6950 Ringkøbing. Agenda as per the articles of association: 1. Election of chairperson The board of directors proposes that Allan Østergaard Sørensen, attorney-at-law, chair the meeting. 2.The board's report on the bank’s activities in the previous year The board of directors proposes that the board’s report be adopted. 3.Presentation of the annual report for approval The board of directors proposes that the annual report be approved. Further reference is made to the published annual report for 2022. 4.Decision on allocation of profit or covering of loss under the approved annual report The board of directors proposes that the distribution of profit be approved. Further reference is made to the published annual report f